Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients

James P. Stewart, Alan T. McGown, Joseph Prendiville, George Pettit, Brian W. Fox, John R. Arrand

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients'. Together they form a unique fingerprint.

Cite this